Empery Asset Management LP Makes New $514.66 Million Investment in SCYNEXIS, Inc. $SCYX

Posted by Brian Himes on Aug 22nd, 2026

Empery Asset Management LP bought a new stake in shares of SCYNEXIS, Inc. (NASDAQ:SCYX – Free Report) during the 2nd quarter, Holdings Channel reports. The fund bought 126,451 shares of the company’s stock, valued at approximately $514,656,000. SCYNEXIS makes up 0.6% of Empery Asset Management LP’s portfolio, making the stock its 18th biggest holding.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in SCYNEXIS in the second quarter worth $169,000. Wealth Effects LLC bought a new stake in SCYNEXIS in the second quarter valued at $56,000. Renaissance Technologies LLC increased its position in SCYNEXIS by 27.6% during the 1st quarter. Renaissance Technologies LLC now owns 224,640 shares of the company’s stock valued at $206,000 after purchasing an additional 48,640 shares during the period. Goldman Sachs Group Inc. purchased a new position in SCYNEXIS during the 4th quarter valued at $1,255,000. Finally, Geode Capital Management LLC raised its holdings in SCYNEXIS by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 449,223 shares of the company’s stock worth $284,000 after purchasing an additional 29,775 shares in the last quarter. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Stock Performance

Shares of SCYX opened at $5.10 on Friday. SCYNEXIS, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $10.48. The firm’s 50-day simple moving average is $4.44 and its two-hundred day simple moving average is $5.83. The stock has a market cap of $50.74 million, a PE ratio of -2.44 and a beta of 1.09.

SCYNEXIS (NASDAQ:SCYX – Get Free Report) last released its earnings results on Monday, August 10th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $1.14. SCYNEXIS had a negative net margin of 41.79% and a negative return on equity of 44.15%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.08 million. Equities research analysts predict that SCYNEXIS, Inc. will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SCYX. Brookline Capital Markets reaffirmed a “buy” rating on shares of SCYNEXIS in a research report on Friday, July 31st. Wall Street Zen upgraded shares of SCYNEXIS from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings raised shares of SCYNEXIS from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 24th. Finally, Guggenheim restated a “buy” rating and issued a $33.00 price objective (up from $24.00) on shares of SCYNEXIS in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $33.00.

View Our Latest Research Report on SCYNEXIS

SCYNEXIS Company Profile

(Free Report)

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.